Specialties

Interventional Cardiology (Board certified since 1999)

Cardiology (Board certified since 1975)

Internal Medicine (Board certified since 1972)

At a Glance

  • 1972 Started practicing
  • 45 Years experience
  • 1 OFFICE LOCATION
  • 1 HOSPITAL AFFILIATION

About Dr. Douglas

My Clinical Interests

  • angina
  • angioplasty/angiogram
  • cardiac catheterization
  • cardiology-beta radiation
  • cardiology - interventional
  • cardiovascular disease
  • myopathy
  • stents

Academic Profile

Training

MEDICAL SCHOOL

Washington University School of Medicine, Seattle, WA

INTERNSHIP

University of North Carolina School of Medicine, Chapel Hill, NC

RESIDENCY

University of North Carolina School of Medicine, Chapel Hill, NC

Grady Health Systems, Atlanta, GA

FELLOWSHIP

Emory University Hospital, Atlanta, GA

Professional Memberships

Dekalb Medical Society

Society for Cardiac Angiography and Interventions

Society for Cardiac Angiography and Intervention Board of Trustees

Honors & Awards

America's Top Doctors, 2001-2011
Atlanta's Top Doctors, 2001-2011

Best Doctor's in America, 2001 - 2011

Atlanta's Top Doctor's, 2001 - 2011
Atlanta Magazine

Major Publications

Vassiliades TA, Kilgo PD, Douglas JS et al, 2010. Hybrid coronary revascularization versus off-pump coronary artery bypass: a prospective evaluation. Innovations, technology and techniques in cardiothoracic and vascular surgery. January 2010.

Leon MB, Mauri L, Popma JJ et al, 2010. A randomized comparison of the ENDEAVOR zotarolimus-eluting stent versus the TAXUS paclitaxel-eluting stent in de novo native coronary lesions 12-month outcomes from the ENDEAVOR IV trial. J Am Coll Cardiol 6:543-54.

Douglas JS Jr, 2009. Are our patients better off with drug-eluting stents in saphenous vein grafts? J Am Coll Cardiol Intv 2:1113-1115.

Leon MB, Kandzari DE, Eisenstein EL, Anstrom KJ, Mauri L, Cutlip DE, Nikolsky E, O’Shaughnessy C, Overlie PA, Kirtane AJ, McLaurin BT, Solomon SL, Douglas JS Jr, et al, 2009. Late safety, efficacy, and cost-effectiveness of zotarolimus-eluting stent compared with a paclitaxel-eluting stent in patients with de novo coronary lesions: 2-year follow-up from the ENDEAVOR IV trial (Randomized, Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Elutint Coronary Stent System Versus the Taxus Paclitaxel-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions). JACC Cardiovasc Interv 12:1208-18.

Ghazzal ZB, Dhawan SS, Sheikh A, Douglas JS, et al, 2009. Usefulness of serum high-density liproprotein cholesterol level as an independent predictor of one-year mortality after percutaneous coronary interventions. A J Cardiol 7:902-6.

Fraker TD Jr, Fihn SD, Gibbons RJ, Abrams J, Douglas JS Jr, et al, 2007. 2007 Chronic angina focused update of the ACC/AHA 2002 Guidelines for the management of patients with chronic stable angina: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines Writing Group to develop the focused update of the 2002 Guidelines for the management of patients with chronic stable angina. Circulation 116:2762-72.

Zhang Z, Foster JK, Kolm P et al, 2006. Reduced 6-month resource use and costs associated with cilostazol in patients after successful coronary stent implanation: results from the Cilostazol for RESTenosis (CREST) trial. Am Heart J 4:770-776.

Douglas JS Jr; 2007. Pharmacologic Approaches To Restenosis Prevention. Am J Cardiol 100:10K-16K.

Locations & Appointments

1 Office Location(s)

1

Emory Clinic at 1365 Clifton Rd
1365 Clifton Rd NE
Atlanta, GA 30322

  • 404-778-5299
S

1 Hospital Affiliation(s)

2

Emory University Hospital

1364 Clifton Rd NE
Atlanta, GA 30322
H

Academic Profile

Training

MEDICAL SCHOOL

Washington University School of Medicine, Seattle, WA

INTERNSHIP

University of North Carolina School of Medicine, Chapel Hill, NC

RESIDENCY

University of North Carolina School of Medicine, Chapel Hill, NC

Grady Health Systems, Atlanta, GA

FELLOWSHIP

Emory University Hospital, Atlanta, GA

Professional Memberships

Dekalb Medical Society

Society for Cardiac Angiography and Interventions

Society for Cardiac Angiography and Intervention Board of Trustees

Honors & Awards

America's Top Doctors, 2001-2011
Atlanta's Top Doctors, 2001-2011

Best Doctor's in America, 2001 - 2011

Atlanta's Top Doctor's, 2001 - 2011
Atlanta Magazine

Major Publications

Vassiliades TA, Kilgo PD, Douglas JS et al, 2010. Hybrid coronary revascularization versus off-pump coronary artery bypass: a prospective evaluation. Innovations, technology and techniques in cardiothoracic and vascular surgery. January 2010.

Leon MB, Mauri L, Popma JJ et al, 2010. A randomized comparison of the ENDEAVOR zotarolimus-eluting stent versus the TAXUS paclitaxel-eluting stent in de novo native coronary lesions 12-month outcomes from the ENDEAVOR IV trial. J Am Coll Cardiol 6:543-54.

Douglas JS Jr, 2009. Are our patients better off with drug-eluting stents in saphenous vein grafts? J Am Coll Cardiol Intv 2:1113-1115.

Leon MB, Kandzari DE, Eisenstein EL, Anstrom KJ, Mauri L, Cutlip DE, Nikolsky E, O’Shaughnessy C, Overlie PA, Kirtane AJ, McLaurin BT, Solomon SL, Douglas JS Jr, et al, 2009. Late safety, efficacy, and cost-effectiveness of zotarolimus-eluting stent compared with a paclitaxel-eluting stent in patients with de novo coronary lesions: 2-year follow-up from the ENDEAVOR IV trial (Randomized, Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Elutint Coronary Stent System Versus the Taxus Paclitaxel-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions). JACC Cardiovasc Interv 12:1208-18.

Ghazzal ZB, Dhawan SS, Sheikh A, Douglas JS, et al, 2009. Usefulness of serum high-density liproprotein cholesterol level as an independent predictor of one-year mortality after percutaneous coronary interventions. A J Cardiol 7:902-6.

Fraker TD Jr, Fihn SD, Gibbons RJ, Abrams J, Douglas JS Jr, et al, 2007. 2007 Chronic angina focused update of the ACC/AHA 2002 Guidelines for the management of patients with chronic stable angina: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines Writing Group to develop the focused update of the 2002 Guidelines for the management of patients with chronic stable angina. Circulation 116:2762-72.

Zhang Z, Foster JK, Kolm P et al, 2006. Reduced 6-month resource use and costs associated with cilostazol in patients after successful coronary stent implanation: results from the Cilostazol for RESTenosis (CREST) trial. Am Heart J 4:770-776.

Douglas JS Jr; 2007. Pharmacologic Approaches To Restenosis Prevention. Am J Cardiol 100:10K-16K.